Feb 11, 2022
Data from several new studies presented this week at the International Stroke Conference (ISC) further validates the best-in-class sensitivity and specificity of Viz.ai’s intelligent care coordination platform for stroke in real world settings across multiple commercial modules.
SAN FRANCISCO & NEW ORLEANS–(BUSINESS WIRE)–Data from several new studies presented this week at the American Heart Association International Stroke Conference (ISC) further validates the best-in-class sensitivity and specificity of Viz.ai’s intelligent care coordination platform for stroke in real world settings across multiple commercial modules. Three posters and one abstract presented at the meeting from three institutions conclude there is a positive impact to workflow and patient care from the use of multiple Viz Platform modules, including Viz LVO (for large vessel occlusion) and Viz ICH (for intracranial hemorrhage).
Real-world data from University of California at San Diego (UCSD), in a poster titled “VISIION: Viz.ai Implementation of Stroke Augmented Intelligence and Communications Platform To Improve Indicators and Outcomes for a Comprehensive Stroke Center and Network,” by Figurelle at al., demonstrated reductions in (door to groin) DTG time of 41 minutes for direct arriving LVO patients in a robust comprehensive stroke center (CSC).
Data from Ohio State University, Wexner, in a poster titled “Real World Experience With Viz.ai Automated Hemorrhage Detection At A Comprehensive Stroke Center,” by Arminian et al., demonstrated the accuracy of Viz ICH in alerting 82 of 83 ICH cases detected by radiologists.
Furthermore, a recent publication from The Mount Sinai Hospital, New York, titled “AI software detection of large vessel occlusion stroke on CT angiography: a real-world prospective diagnostic test accuracy study,” by Matsoukas et al., presented data from a study of 1,822 CTA scans demonstrating detection rates of 100% and 93% for ICA terminus (ICA-T) and M1 occlusions, respectively. The authors concluded, “In this work, the diagnostic accuracy of Viz LVO was tested in real life and real time across one of the to-date largest prospective consecutive cohorts, in a multiple-tiered healthcare system. Viz LVO is a promising AI-driven software that can reliably detect ICA-T and M1 LVOs with impressive NPV, sensitivity, and overall accuracy. It is a useful adjunct in triaging patients with a LVO stroke at varying levels of stroke centers.”
An additional abstract from the same center studied 682 patients analyzed with Viz ICH and found an overall accuracy of 99%. “Viz ICH has the potential to be an adjunct tool to streamline ICH triage, reduce treatment delays, and improve outcomes of patients presenting with ICH,” concluded the authors.
“This new real world data further demonstrates the unparalleled accuracy of the Viz platform, which results in time savings and improved stroke patient outcomes,” said Jayme Strauss, chief clinical officer of Viz.ai.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,400+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies.